Theravance Biopharma reports Q4 EPS (17c), consensus (15c)

Reports Q4 revenue $17.565M, consensus $17.68M. “The Theravance team delivered a strong performance in 2023, having achieved our financial objectives in the fourth quarter and exceeded our aggressive annual goal for YUPELRI hospital growth,” said Rick E Winningham, Chief Executive Officer. “We look forward to continuing YUPELRI net sales growth in 2024 and completing enrollment in the CYPRESS study in the second half of this year. Further, we are excited to host a virtual investor event in the second quarter, where both MSA thought leaders and members of Theravance’s senior management team will review the science underpinning our expectation that ampreloxetine can provide clinical benefits in MSA patients with nOH.”